Edoxaban dosing patterns in real life practice – Results from the DRESDEN NOAC REGISTRY
Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for venous thromboembolism treatment or stroke prevention in atrial fibrillation. Effectiveness and safety of edoxaban depends on adequate dosing, for which renal function, body weight and drug-drug interactions are important....
Main Authors: | Jan Beyer-Westendorf, Sandra Marten, Christiane Naue, Christina Köhler, Luise Tittl, Martin Bornhäuser |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-12-01
|
Series: | Thrombosis Update |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666572721000390 |
Similar Items
-
Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry
by: Jan Beyer-Westendorf, et al.
Published: (2021-04-01) -
Edoxaban-related Spontaneous Renal Hematoma: A Case Report
by: Ayberk Iplikci, et al.
Published: (2020-10-01) -
Factors associated with bleeding events during catheter ablation with uninterrupted periprocedural edoxaban for atrial fibrillation: a subanalysis of the KYU-RABLE study
by: Ichitaro Abe, et al.
Published: (2021-08-01) -
Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study
by: Ippei Ikushima, et al.
Published: (2020-06-01) -
Elderly patients with atrial fibrillation in routine clinical practice—peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study
by: M. Unverdorben, et al.
Published: (2020-12-01)